As an industry expert, was invited by IMC to join Advisory colleagues to discuss Drug Plan management and the impact to our private payor clients.
Invited to attend a Virtual Policy forum with various industry experts (Insurers, Pharmacist, Pharma, etc) to discuss the implications and challenges for the future of National Pharmacare on October 20, 2020.
Chris was invited to review and comment on the new IMC Cost Drivers Analysis of Private Drug Plans in Canada (2016-2019) with a handful of successful benefit consultants, in a series of virtual meetings. The meeting was intended to get our input on the new data and to answer some focused questions on key findings [...]
Great article by Cassandra Williamson-Hopp on the moves taken by Ontario Power Generation in the area of virtual care. Providing leading edge benefits for their insured members and dependents is clearly a priority and we to see the uptake of these services as a landscape changer. For our part, we are recommending free services like [...]
Many thanks to Benefits Canada for publishing my latest article on what we saw in 2019 and earlier with respect to premium benefits cost trends. All too often, we are hearing from Insurers and those publishing their 'trend surveys' that high single digit costs escalations should be expected; given high cost drugs, etc. Then, not surprising [...]
